A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy
Hemophilia A is a genetic disorder that results in the deficiency of functional factor VIII protein, which plays a key role in blood coagulation. Currently, the majority of hemophilia A patients are treated with repeated infusions of factor VIII protein. Approximately 30% of severe hemophilia A pati...
Main Authors: | Alex C. Chen, Xiaohe Cai, Chong Li, Liliane Khoryati, Marc A. Gavin, Carol H. Miao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-04-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.00638/full |
Similar Items
-
Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy
by: Volkan Karakuş, et al.
Published: (2012-05-01) -
Extended half-life recombinant factor VIII treatment of hemophilia A in Brazil: an expert consensus statement
by: Margareth Castro Ozelo, et al.
Published: (2024-01-01) -
Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021
by: Yesim Dargaud, et al.
Published: (2021-12-01) -
Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors
by: Claude Négrier, et al.
Published: (2022-05-01) -
Genetic Characterization of the Factor VIII Gene in a Cohort of Colombian Patients with Severe Hemophilia A with Inhibitors
by: Samuel Sarmiento Doncel, et al.
Published: (2022-05-01)